News & Insights Blog

uMed Launches SnapACCESS: A Groundbreaking Solution for Agile and Compliant Patient Data Insights in Diabetes and Obesity Research

London, UK – Thursday 1 May — uMed, a leading innovator in healthcare technology, is proud to announce the launch of SnapACCESS — a revolutionary new platform designed to transform how pharmaceutical companies access and leverage patient data to support faster, smarter drug development. The first rollout will focus on the critical cardiometabolic disease (CMD) area, particularly diabetes and obesity.

SnapACCESS empowers pharmaceutical teams with compliant, agile access to highly targeted, clinically confirmed patient groups, including detailed insights into patients’ real-world treatment journeys — such as the medications they are currently prescribed. This uniquely enables organizations to optimize study design, site selection, and early feasibility assessments with unprecedented speed and precision.

“SnapACCESS solves a problem common across academia and industry,” said Professor Mark Toshner, Director at Cambridge Heart & Lung Institute. “By combining rapid, compliant access to real-world clinical data with direct patient engagement, we are not just speeding up research — we are elevating its quality. This is a transformative step towards more patient-centered, data-driven drug development.”

A New Standard for Integrated Data and Patient Engagement

Unlike traditional retrospective datasets or self-reported patient panels, SnapACCESS offers a dynamic, twofold advantage:

Full access to linked electronic health record (EHR) data, delivering real-time insights into patients’ medical histories, comorbidities, treatment pathways, and outcomes.
Direct patient engagement through uMed’s dedicated nurse support and patient services team, ensuring patients fully understand research questions and allowing for adaptive follow-up interactions to capture deeper insights.

This approach not only ensures regulatory-grade compliance (IRB/REC approved, GDPR/HIPAA compliant) but also enables repeatable, high-quality interactions with pre-consented patients — a vital advantage for iterative research and longitudinal studies.

Delivering Actionable Insights in Under 4 Weeks

SnapACCESS is built for agility:

Insights delivered in under four weeks
Interactive, AI-powered dashboards for real-time data exploration
Flexible question structures and the ability to re-engage patient cohorts
Rapid segmentation by clinical markers, treatments, and outcomes

Pharmaceutical companies can quickly refine their strategies, validate market insights, enhance clinical narratives, and accelerate trial readiness — driving more effective therapies to market faster.

Focused Launch with Expansion Plans

SnapACCESS initially targets diabetes and obesity patient cohorts, supported by uMed’s growing network of over 5,500 active patients, with ongoing enrollment expanding by 1,000+ patients per month.

Future expansions will broaden access to additional therapeutic areas across the cardiometabolic spectrum and beyond.

About uMed
uMed is a technology-driven healthcare platform committed to transforming the future of clinical research by enabling healthcare providers and life science organizations to drive faster, smarter, patient-centered studies without burdening clinical teams.

Contact:
Dr. Matt Wilson, MD
matt.wilson@umed.io
www.umed.io

News & Insights Blog

The Future of Obesity Pharmacology: Bridging Evidence Gaps with a New Model for Clinical Registries

In this article with Pharmaceutical Executive, uMed CEO & Founder, Dr Matt Wilson, discusses the need for robust evidence that goes beyond just routinely collected data and that accurately reflects the diverse patient populations affected by obesity.

By leveraging advanced data collection methods, including patient-reported outcomes and digital health tools, the healthcare industry can build stronger evidence, enhancing the personalization and effectiveness of obesity treatments for broader populations. This shift promises to bridge gaps in clinical research and support better decision-making across the pharmaceutical and healthcare sectors.

Read the full article here.

News & Insights Blog

Patient Story: Kevin Quinn

In 2022, Kevin Quinn from Liverpool joined a uMed supported study of patients with chronic respiratory conditions. The study evaluated the effectiveness of a respiratory monitor that measures CO2 levels in tidal breathing of participants. The aim of the research was to help advance the development of point-of-care diagnostic technologies that monitor and manage cardiorespiratory conditions, which have the potential to transform the way we diagnose and treat patients.

We caught up with Kevin upon completion of the study to find out more about his reasons for taking part and to hear about his experiences of participating in this research with uMed. Find out what he had to say…

Why did you choose to join this study?

I had been suffering from a lung condition for some time, so when I received the message about this study from my GP, I was keen to get involved and support any research that had the potential to improve knowledge and understanding of respiratory conditions, and that might bring some relief to others in the future.

How would you describe your experience of taking part in this study?

The whole process went smoothly, uMed handled everything so I was able to participate entirely from home and didn’t have to travel!

I was called by uMed’s Lead Research Nurse, Hannah, who was extremely helpful and professional in talking me through the study and ensuring I was happy to proceed.

I then received a study questionnaire and the respiratory device via post, and the uMed team walked me through how to use the device and how to record my daily symptoms. They also arranged for return of the devices once the study had finished.

I only have praise for the uMed team, their support was 10 out of 10! In particular Hannah was extremely helpful, friendly and professional, and was available to answer any questions I had about the study. This made me, and my wife, feel completely at ease with taking part.

What message do you have for others about participating in research?

Participating in research is so important. As individuals we own all this important information about our health that if shared could have a great impact on the lives of others in the future. How else can new treatments be developed if we don’t share this information?

Want to find out more about this study?

Find out how uMed supported the successful enrolment of 740 patients in to this study, whilst also handling device distribution, device training, and the collection and aggregation of key data to demonstrate efficacy of the device. Read the full case study here.